Wisconsin Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Wisconsin is / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in WI, recent WI mesothelioma-related court cases, mesothelioma specialists in WI and potential asbestos hotspots in Wisconsin.
Wisconsin Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Wisconsin
Wisconsin Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Wisconsin Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Wisconsin Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Wisconsin Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Wisconsin Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
State v. Harenda Enters.
No. 2005AP1829, SUPREME COURT OF WISCONSIN, March 13, 2008, Filed
No. 2005AP1829, SUPREME COURT OF WISCONSIN, March 13, 2008, Filed
Sopha v. Owens-Corning Fiberglas Corp.
No. 98-1343, SUPREME COURT OF WISCONSIN, September 10, 1999 , October 27, 1999, Opinion Filed
No. 98-1343, SUPREME COURT OF WISCONSIN, September 10, 1999 , October 27, 1999, Opinion Filed
Tatera v. FMC Corp.
Appeal No. 2008AP170, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, May 12, 2009, Decided, May 12, 2009, Filed
Appeal No. 2008AP170, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, May 12, 2009, Decided, May 12, 2009, Filed
Zielinski v. A.P. Green Indus.
Appeal No. 02-1888 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, February 4, 2003, Submitted On Briefs , March 18, 2003, Decided , March 18, 2003, Filed
Appeal No. 02-1888 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, February 4, 2003, Submitted On Briefs , March 18, 2003, Decided , March 18, 2003, Filed
Anderson v. Combustion Eng'g, Inc.
Appeal No. 01-1518, COURT OF APPEALS OF WISCONSIN, DISTRICT I, May 7, 2002, Oral Argument , May 21, 2002, Decided , May 21, 2002, Filed
Appeal No. 01-1518, COURT OF APPEALS OF WISCONSIN, DISTRICT I, May 7, 2002, Oral Argument , May 21, 2002, Decided , May 21, 2002, Filed
Int'l Paper Co. v. Labor & Indus. Review Comm'n
No. 01-0126, COURT OF APPEALS OF WISCONSIN, DISTRICT THREE, July 23, 2001, Submitted On Briefs , September 25, 2001, Decided , September 25, 2001, Filed
No. 01-0126, COURT OF APPEALS OF WISCONSIN, DISTRICT THREE, July 23, 2001, Submitted On Briefs , September 25, 2001, Decided , September 25, 2001, Filed
Kasun v. Owens-Illinois, Inc.
No. 00-2550, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, August 14, 2001, Decided , August 14, 2001, Filed
No. 00-2550, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, August 14, 2001, Decided , August 14, 2001, Filed
Sybron Int'l Corp. v. Sec. Ins. Co.
No. 99-3050 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, March 6, 2001, Decided , March 6, 2001, Filed
No. 99-3050 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, March 6, 2001, Decided , March 6, 2001, Filed
Stendahl v. A & M Insulation Co.
No. 99-0212, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, October 10, 2000, Decided , October 10, 2000, Filed
No. 99-0212, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, October 10, 2000, Decided , October 10, 2000, Filed
Hospitals and Cancer Centers
Physicians
Joan H. Schiller, M.D.
H. Ian Robins, M.D.
University of Wisconsin
Madison, WI
Physicians
Joan H. Schiller, M.D.
H. Ian Robins, M.D.
University of Wisconsin
Madison, WI
| City | Site |
| Fond Du Lac |
Pig Iron Foundry |
| Madison |
AT&T Burlington Plant Veterans Admin Hospital |
| Milwaukee |
A.O. Smith Foundry Brookfield Square Crusper Steel Faulk's Steel Milwaukee Powerhouse Oak Creek Power Plant Southridge Mall Cutler Hammer Foundry |
| Oak Creek |
Wisconsin Electric Power Company |
| Port Edwards |
Port Edwards Paper Co. |
| Stevens Point |
Whiting Paper Mill |
| Wausau |
Wisconsin Public Service Company |
| West Bend |
West Bend Co |
Research
Raines, Ronald T. Ribonucleases In Cancer Chemotherapy
Grant: 2R01CA073808-04
Grant: 2R01CA073808-04
Abstract:
DESCRIPTION (from applicant's abstract): The overall goal of the proposed
research is to reveal how homologs and variants of ribonuclease A (RNase A)
promote tumor cell death. Onconase, which is an amphibian homolog of RNase A,
is now undergoing Phase III human clinical trials for the treatment of
malignant mesothelioma and Phase I/II trials for the treatment of metastatic
renal carcinoma. In contrast to onconase, RNase A is not cytotoxic. In the
initial funding period, variants of RNase A were created that, like onconase,
were able to evade the endogenous ribonuclease inhibitor protein (RI) that
resides in the cytosol of mammalian cells. These variants were toxic to tumor
cells. This finding portends the development of a new class of cancer
chemotherapeutics based on homologs and variants of RNase A.
The specific aims of the proposed research are: (1) to determine how RNase A
homologs bind to the cell surface, (2) to discover the route taken by RNase A
homologs to cytosolic RNA, (3) to reveal fundamental information about the
subcellular localization and intracellular function of RI, and (4) to create a
human homolog of RNase A that is more toxic to tumor cells than onconase.
Relevant properties of RNase A homologs and variants will be assessed in
comparison to onconase (positive control) and wild-type RNase A (negative
control). These properties include cytotoxicity, RI evasion, ribonucleolytic
activity, and conformational stability. Finally, the three-dimensional
structures of RNase A homologs and variants with notable cytotoxicity will be
determined by X-ray diffraction analysis.
The proposed research is designed to reveal new insights into the basis of
ribonuclease cytotoxicity, and could lead to new cancer chemotherapeutics.
Tags: Antineoplastic, Cytotoxicity, Enzyme Activity, Enzyme Inhibitor, Pancreatic Ribonuclease Rna, Conformation, Drug Design /synthesis /production, Intracellular Transport X Ray Crystallography, Protein Engineering
Tags: Antineoplastic, Cytotoxicity, Enzyme Activity, Enzyme Inhibitor, Pancreatic Ribonuclease Rna, Conformation, Drug Design /synthesis /production, Intracellular Transport X Ray Crystallography, Protein Engineering
- Followup Grant: 5R01CA073808-05
- Followup Grant: 5R01CA073808-06
- Followup Grant: 5R01CA073808-07
- Followup Grant: 2R01CA073808-08
- Followup Grant: 5R01CA073808-09
- Followup Grant: 5R01CA073808-10
- Followup Grant: 5R01CA073808-11
Schiller, Joan H. Mid Career Investigator Award
Grant: 1K24CA084172-01
Grant: 1K24CA084172-01
Abstract:
DESCRIPTION: (Applicant's Description) This application proposes Joan H.
Schiller, M.D., for a K24 Mid-Career Investigator Award in Patient Oriented
Research. Dr. Schiller is currently one of only two tenured women physicians
in the University of Wisconsin Department of Medicine, and an accomplished
medical oncologist with an active clinical and translational research program
in lung cancer. Dr. Schiller is active in drug development in lung cancer,
participating at all levels of clinical research, including Phase I, II, and
III trials. In addition to running an active Phase II program at the UW and
participating in the UWCCC Phase I program, she is co-chair of the Eastern Co-
Operative Group (ECOG) Thoracic Committee, and chair of two ECOG multi-
institutional Phase III studies. Dr. Schiller intends to use the release time
from her heavy clinical and administrative responsibilities to expand her
scope of clinical research in lung cancer, develop a mentoring program for
young investigators, and to further develop her own mentoring and leadership
skills. Her specific aims within this award are (1) to draw upon the
considerable campus-wide resources in basic and translational research at the
UW, so as to facilitate interdisciplinary collaborations and development of a
UW clinical lung cancer research program that engages the participation of
researchers from multiple disciplines; (2) to develop a mentoring program for
residents and fellows for tobacco-related neoplasms and associated clinical
research, (3) to support her activities in clinical research in lung cancer,
and enhance her own development as an academic leader in the field of lung
cancer, and (4) to foster the career development of women clinical scientists
and leaders in academic medicine. In this application, Dr. Schiller
demonstrates (a) her strong clinical research interest in lung cancer, and
accomplishments in the field; (b) an outstanding basic science and clinical
environment within the UW in which to conduct patient-oriented, translational
research; (c) her unique position within the institution to nurture the
careers of women junior investigators, and (d) the need for protected research
time to continue these efforts.
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Mesothelioma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Radiation Therapy, Nonsmall Cell Lung Cancer, Small Cell Lung Cancer Angiogenesis Inhibitor, Carboplatin, Cis Platinum Compound, Clinical Trial Phase I, Clinical Trial Phase Ii /iii /iv, Cyclophosphamide, Doxorubicin, Etoposide, Gemcitabine, Guanine Nucleotide Binding Protein, P53 Gene /protein, Paclitaxel, Role Model, Topotecan, Vinblastine, Vincristine Clinical Research, Human Subject
Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Mesothelioma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Radiation Therapy, Nonsmall Cell Lung Cancer, Small Cell Lung Cancer Angiogenesis Inhibitor, Carboplatin, Cis Platinum Compound, Clinical Trial Phase I, Clinical Trial Phase Ii /iii /iv, Cyclophosphamide, Doxorubicin, Etoposide, Gemcitabine, Guanine Nucleotide Binding Protein, P53 Gene /protein, Paclitaxel, Role Model, Topotecan, Vinblastine, Vincristine Clinical Research, Human Subject
- Followup Grant: 5K24CA084172-02
- Followup Grant: 5K24CA084172-03
- Followup Grant: 5K24CA084172-04
- Followup Grant: 5K24CA084172-05
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate; Other: laboratory biomarker analysis
More Information
Intervention: Drug: cediranib maleate; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
